US equities
|
NVDA
$243.15
▲+1.78%
SPCX
$173.46
▲+1.38%
MU
$1,069.80
▲+0.55%
AMD
$646.42
▲+2.32%
META
$743.91
▲+0.27%
AMZN
$252.17
▲+0.31%
SNDK
$1,715.00
▲+0.64%
INTC
$117.53
▲+1.16%
NVDA
$243.15
▲+1.78%
SPCX
$173.46
▲+1.38%
MU
$1,069.80
▲+0.55%
AMD
$646.42
▲+2.32%
META
$743.91
▲+0.27%
AMZN
$252.17
▲+0.31%
SNDK
$1,715.00
▲+0.64%
INTC
$117.53
▲+1.16%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Invesco Pharmaceuticals ETF
(NY:
PJP
)
121.72
+0.62 (+0.51%)
Delayed Quote
Updated: 9:30 AM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Invesco Pharmaceuticals ETF
< Previous
1
2
Next >
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
↗
October 02, 2026
VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.
Via
The Motley Fool
Topics
ETFs
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks
↗
September 23, 2026
XLV's broader diversification and lower fees appeal to cost-conscious investors, while PJP's concentrated pharma bet has outperformed over the past year.
Via
The Motley Fool
Topics
ETFs
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits
↗
September 08, 2026
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
Via
The Motley Fool
Topics
ETFs
Merck’s Blockbuster Drug Keytruda Gets Canadian Regulator’s Approval For Treating Cervical Cancer: Retail Investors Appear Divided
↗
July 21, 2025
Via
Stocktwits
Which Healthcare ETF Offers the Better Growth Outlook: VanEck Biotech or Invesco Pharmaceuticals?
↗
August 28, 2026
VanEck focuses on a clutch of biotech leaders with lower fees; Invesco tracks a select group of pharma companies with higher dividend yield and stronger five-year returns.
Via
The Motley Fool
Topics
ETFs
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?
↗
August 23, 2026
Here's how Invesco's concentrated pharma play compares to Fidelity's diversified approach to healthcare stocks.
Via
The Motley Fool
Topics
ETFs
Invesco Nasdaq Biotech vs. Invesco Pharma: How Do These ETFs Stack Up?
↗
August 19, 2026
One offers concentrated exposure to 29 pharma giants with lower volatility, while the other provides broader diversification across 251 biotech companies at a cheaper cost.
Via
The Motley Fool
Topics
ETFs
XPH vs PJP: Which Pharma ETF Offers Better Value
↗
August 17, 2026
State Street's lower costs appeal to buy-and-hold investors, while Invesco's concentrated portfolio and lower volatility suit risk-averse income seekers.
Via
The Motley Fool
Topics
ETFs
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?
↗
July 22, 2026
PJP surged 45% in one year, but VHT's lower costs and higher dividend yield appeal to long-term income investors seeking broad sector exposure.
Via
The Motley Fool
Topics
ETFs
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
↗
July 20, 2026
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
Via
The Motley Fool
Topics
ETFs
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
↗
July 20, 2026
PJP delivered a higher return over the past year -- but IYH charges lower fees and pays a higher dividend yield.
Via
The Motley Fool
Topics
ETFs
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
↗
July 09, 2026
PJP delivers lower volatility and higher income with concentrated pharma exposure, while XBI offers broader biotech growth at lower cost.
Via
The Motley Fool
Topics
ETFs
Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?
↗
July 08, 2026
PJP delivered stronger 5-year returns with lower volatility, while FBT offers broader biotech exposure at a slightly cheaper cost.
Via
The Motley Fool
Topics
ETFs
IHE vs. PJP: Which Pharmaceutical ETF Is the Better Buy for Investors?
↗
July 05, 2026
Compare the portfolio concentration, risk profiles, and long-term growth of these two pharma ETFs.
Via
The Motley Fool
Topics
ETFs
Intellectual Property
Which Pharmaceutical ETF Is Better, VanEck's PPH or Invesco's PJP?
↗
July 04, 2026
Compare portfolio concentration, risk profiles, and long-term growth as these two pharma ETFs take different approaches to capturing sector opportunity.
Via
The Motley Fool
Topics
ETFs
State Street Health Care ETF Tops Invesco Pharma on Cost and Size
↗
July 04, 2026
Compare sector breadth, yield, and recent performance as these two healthcare ETFs take different approaches to growth and income.
Via
The Motley Fool
Topics
ETFs
Invesco's RSPH vs. PJP: Which Health Care ETF Is the Better Fund For The GLP-1 Revolution?
↗
June 15, 2026
Compare portfolio strategies, cost structures, and risk profiles as two Invesco healthcare ETFs take different paths to sector exposure.
Via
The Motley Fool
Topics
ETFs
Healthcare ETFs: PJP Focuses on Pharmaceuticals, While XBI Zeroes in on Biotech
↗
June 05, 2026
Compare risk profiles, dividend strategies, and portfolio concentration as these two healthcare ETFs take different paths to long-term returns.
Via
The Motley Fool
Topics
ETFs
Why Did CANF Stock Soar 40% In Pre-Market Today?
↗
March 04, 2026
The company said its trial to study the treatment of patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.
Via
Stocktwits
Merck Is Reportedly Splitting Its Pharma Division As Keytruda Patent Nears 2028 Expiry
↗
February 23, 2026
According to a Wall Street Journal report, the drugmaker said it will reorganize its human health segment into two separate units in an effort to better position its portfolio for the years ahead.
Via
Stocktwits
Topics
Intellectual Property
FDA Commissioner Raises Concerns About US Pharma Lagging Behind China In Drug Development
↗
February 18, 2026
Marty Makary, in an interview with CNBC, further called for reforms that could streamline the process for starting trials on new treatments.
Via
Stocktwits
Topics
ETFs
Government
Why Did OCUL Stock Jump 13% In Pre-Market Today?
↗
January 15, 2026
French pharmaceutical giant Sanofi is preparing an offer to acquire the American biopharmaceutical firm, according to a report by French publication La Lettre.
Via
Stocktwits
US-UK Near Landmark Zero-Tariffs Pharma Deal, Announcement Expected Soon: Report
↗
December 01, 2025
The report states that the agreement between the U.S. and the U.K. is expected to be announced in the coming days.
Via
Stocktwits
Topics
World Trade
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
↗
November 12, 2025
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
Via
Benzinga
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
↗
September 29, 2025
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
Via
Benzinga
Topics
Government
World Trade
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
↗
September 08, 2025
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
Via
Benzinga
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
↗
August 01, 2025
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
Via
Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
↗
July 16, 2025
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
Via
Benzinga
Topics
Government
World Trade
FDA May Fast-Track New Drug Reviews In Return For Companies Lowering Drug Prices: Report
↗
July 11, 2025
FDA Commissioner Marty Makary floated the idea in an interview on Bloomberg Television.
Via
Stocktwits
Topics
Government
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
↗
July 11, 2025
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
Via
Benzinga
Topics
Government
World Trade
< Previous
1
2
Next >
